Jill Jene
Director/Board Member at LIPOCINE INC.
Net worth: - $ as of 2024-04-29
Profile
Jill M.
Jene is an Independent Director at Lipocine, Inc. She previously worked as Vice President-Business Development at Assertio Therapeutics, Inc. from 2006 to 2017.
She also held the position of Senior Vice President-Business Development at Aria Pharmaceuticals, Inc. from 2017 to 2018, Vice President-Business Development at PDL BioPharma, Inc. from 2018 to 2020, and Head-Corporate Development & Strategy at Adamas Pharmaceuticals LLC from 2020 to 2021.
Dr. Jene has an undergraduate degree from Bradley University, a graduate degree and a doctorate from Northwestern University, and an MBA from DePaul University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
LIPOCINE INC
-.--% | 2024-03-30 | 0 ( -.--% ) | - $ | 2024-04-29 |
Jill Jene active positions
| Companies | Position | Start |
|---|---|---|
| LIPOCINE INC. | Director/Board Member | 2022-04-10 |
Former positions of Jill Jene
| Companies | Position | End |
|---|---|---|
| ADAMAS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2021-11-23 |
| PDL BIOPHARMA, INC. | Corporate Officer/Principal | 2020-08-14 |
Aria Pharmaceuticals, Inc.
 Aria Pharmaceuticals, Inc. Drugstore ChainsRetail Trade twoXAR, Inc. provides drug discovery services. Its DUMA platform rapidly evaluates massive public and proprietary datasets to identify and rank probability drug-disease matches. The company was founded by Andrew A. Radin and Andrew M. Radin in 2014 and is headquartered in Palo Alto, CA. | Corporate Officer/Principal | 2018-04-30 |
Assertio Therapeutics, Inc.
 Assertio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL. | Corporate Officer/Principal | 2017-04-30 |
Training of Jill Jene
| Northwestern University | Doctorate Degree |
| DePaul University | Masters Business Admin |
| Bradley University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| LIPOCINE INC. | Health Technology |
| Private companies | 4 |
|---|---|
PDL BioPharma, Inc.
 PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL. | Health Technology |
Aria Pharmaceuticals, Inc.
Aria Pharmaceuticals, Inc. Drugstore ChainsRetail Trade twoXAR, Inc. provides drug discovery services. Its DUMA platform rapidly evaluates massive public and proprietary datasets to identify and rank probability drug-disease matches. The company was founded by Andrew A. Radin and Andrew M. Radin in 2014 and is headquartered in Palo Alto, CA. | Retail Trade |
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
- Stock Market
- Insiders
- Jill Jene
